Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.54 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5997889 | 0.99 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3831053 | 0.77 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5995221 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL6782599 | 0.74 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5997626 | 0.74 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3832879 | 0.74 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL7133684 | 0.73 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2081810 | 0.73 | CHRNA3 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2081806 | 0.73 | CHRNA3 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5685941 | 0.71 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | CHRNB2 18/4885CHRNA4 8/4885CHRNB4 20/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB2 19/4885CHRNA4 4/4885CHRNB4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.